Section Editors: Gustavo Saposnik, MD, and Daniel Strbian, MD, PhD

EXTEND Trial

Towards a More Inclusive But Complex Thrombolysis

Enrique C. Leira, MD, MS; Keith W. Muir, MD

For most patients with acute ischaemic stroke, the the odds of benefit from intravenous alteplase decline steeply over the first 4.5 hours.[1] This decay curve is derived from trials in which all participants were selected on the basis of noncontrast computed tomography (CT), which is widely available and valuable to exclude hemorrhage or other structural contraindications to treatment. However, non-contrast CT has inherently low sensitivity to early ischemic changes and limited ability to discriminate irreversibly damaged from viable tissue.

Arrival at hospital outside the 4.5 hour time window or uncertainty about time of onset, most commonly due to waking with stroke, have restricted eligibility for intravenous thrombolysis.[2] More advanced physiological imaging has suggested that this short time window may be too conservative for some, including those termed "slow progressors"[3] with favourable leptomeningeal collateral circulation who are able to sustain a small core/large penumbra perfusion pattern (the target mismatch profile) over longer periods of time.

Wide variation among sites in imaging protocols, inconsistent post-processing, and small sample sizes, likely contributed to unsuccessful initial efforts to utilize physiological imaging biomarkers for thrombolysis eligibility beyond the 3 or 4.5 hour window based on CT perfusion or magnetic resonance imaging diffusion-perfusion mismatch patterns (Table).

The imaging criteria used to identify the optimal responder population were initially variable[16] but have been refined with successive trials, and have been exploited successfully in several recent reperfusion trials. Among those with CT perfusion-defined target mismatch, tenecteplase has been shown to be potentially superior to alteplase,[17,18] while in trials of mechanical thrombectomy (all patients in the EXTEND-IA trial [Extending the Time for Thrombolysis in Emergency Neurological Deficits — Intra-Arterial][19] and many in the SWIFT PRIME trial [Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment][20]) effect sizes were larger with perfusion imaging selection compared with trials that used noncontrast CT brain imaging alone.

The EXTEND trial (Extending the Time for Thrombolysis in Emergency Neurological Deficits) tested the hypothesis that intravenous alteplase improves 3-month functional outcomes when given in the 4.5 to 9 hour window to patients with salvageable penumbra as defined by a commercially available automated software package. The trial used rigorous methodology with a relevant primary end-point (modified Rankin Scale, 0–1), adjusted for baseline stroke severity. The trial permitted inclusion of a broad range of patients (baseline National Institutes of Health Stroke Scale score, 4–26), with a definition of viable tissue (ratio 1.2 or <10 mL difference, <70 mL core) more libera than other recent trials. The trial was stopped after recruitment of 225 of the 310 planned patients due to loss of equipoise after publication of the WAKE-UP trial (Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke),[11] which demonstrated significant benefit from alteplase based on FLAIR-DWI mismatch criteria. Exclusion of patients in whom mechanical thrombectomy was planned presumably led to loss of some recruitment among those fulfilling criteria for the DAWN (DWI or CTP Assessment With Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention With Trevo) or DEFUSE-3 (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke) trials in the latter stages.

Data on how many patients were screened and judged ineligible are unavailable but would be relevant for planning systems of care. Prior trials suggest exclusion of around 80% of clinically-eligible patients by CT perfusion physiological imaging selection.[17] Magnetic resonance imaging FLAIR-diffusion mismatch excluded two thirds in the WAKE-UP trial.[11] Despite inclusive clinical and radiological criteria, the study enrolled moderately severe strokes (median National Institutes of Health Stroke Scale score 12, ≈70% having large vessel occlusion), with a very favourable ratio between core (2.4–4.6 mL) and hypoperfusion (74–78 mL). Intervention and control groups were generally well balanced, but alteplase-treated patients were slightly older, and with more severe strokes as measured by both core volume and National Institutes of Health Stroke Scale score. Around 65% woke with symptoms present, therefore median onset-to-treatment time of around 7.5 hours reflects predominantly estimated onset time. The null hypothesis was rejected after

Received June 12, 2019; final revision received July 16, 2019; accepted July 17, 2019.

From the Division of Cerebrovascular Diseases, University of Iowa (E.C.L.); and Institute of Neuroscience & Psychology, University of Glasgow, United Kingdom (K.W.M.).

Correspondence to Keith W. Muir, MD, Institute of Neuroscience & Psychology, University of Glasgow, Queen Elizabeth University Hospital, Glasgow G51 4TF, United Kingdom. Email keith.muir@glasgow.ac.uk

(*Stroke*. 2019;50:2637-2639. DOI: 10.1161/STROKEAHA.119.026249.)

Table. Previous Randomized Clinical Trials of Intravenous Thrombolysis and Thrombectomy Based on Imaging Biomarkers in Extended Time Windows (>4.5 Hours Since Onset)

Trial	Year	Time Window	Imaging Methods
Intravenous thrombolysis			
DIAS[4]	2005	3–6 h	MRI diffusion-perfusion mismatch
DEDAS[5]	2006	3–9 h	MRI diffusion-perfusion mismatch
EPITHET[6]	2008	3–9 h	MRI diffusion-perfusion mismatch
DIAS-2[7]	2009	3–9 h	MRI diffusion-perfusion mismatch or CTP
DIAS-3[8]	2015	3–9 h	Intracranial large vessel occlusion
DIAS-4[9]	2016	3–9 h	Intracranial large vessel occlusion
EXTEND[10]	2018	4.5–9 h	CTP
WAKE-UP[11]	2018	4.5 h after waking	MRI diffusion-FLAIR mismatch
ECASS-4[12]	2019	4.5–9 h	MRI diffusion-perfusion mismatch
Mechanical thrombectomy			
MR RESCUE[13]	2013	8 h	MRI diffusion-perfusion mismatch
DAWN[14]	2018	6–24 h	CTP defined core, or MRI DWI core
DEFUSE-3[15]	2018	6–16 h	Defined core and mismatch ratio on either CTP or MRI

CTP indicates computed tomography perfusion; DAWN, DWI or CTP Assessment With Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention With Trevo; DEDAS, Dose Escalation of Desmoteplase for Acute ischemic Stroke; DIAS, Desmoteplase in Acute Ischemic Stroke; DEFUSE-3, Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke; ECASS-4, European Cooperative Acute Stroke Study 4; EPITHET, Echo-Planar Imaging Thrombolytic Evaluation Trial; EXTEND, Extending the Time for Thrombolysis in Emergency Neurological Deficits; MRI, magnetic resonance imaging; MR RESCUE, Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy; and WAKE-UP, Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke.

preplanned adjustment for age and baseline severity (35.4% versus 29.5% achieved modified Rankin Scale score, 0 to 1, OR 1.44 (1.01–2.06). No differences were observed in the modified Rankin Scale distribution analysis, but a higher proportion of alteplase-treated patients had major early neurological improvement, attained independent recovery (modified Rankin Scale score, 0–2 at day 90), and had imaging evidence of recanalization and reperfusion at 24 hours. As expected, alteplase-treated patients had an excess of symptomatic intracranial hemorrhage (6.2% versus 0.9%)

EXTEND,[10] and an individual patient data pooled analysis of EXTEND, ECASS-4 (European Cooperative Acute Stroke Study 4) and EPITHET (Echo-Planar Imaging Thrombolytic Evaluation Trial),[21] provide further evidence supporting the concept that tissue viability on physiological imaging should be used for reperfusion therapy selection beyond the 4.5 hour window or when onset time is uncertain, adding to[10,21] evidence from WAKE-UP,[11] DAWN,[14] and DEFUSE-3.[15] EXTEND offers a longer time window for intervention in some by calculating estimated onset time as mid-way between last being well and imaging, whereas WAKE-UP required treatment within 4.5 hours of symptom recognition. The use of the same CT perfusion technology often employed to screen for mechanical thrombectomy eligibility is a logistical strength. It remains unanswered whether thrombolytic drugs should be administered to late-window patients with large vessel occlusion eligible for mechanical thrombectomy when mechanical thrombectomy is immediately available, since that scenario was not tested in EXTEND.

EXTEND consolidates the concept of determining treatment eligibility based on physiological imaging rather than noncontrast CT and the clock. Perfusion-based selection, as deployed in EXTEND, or magnetic resonance imaging-based selection as per WAKE-UP, offer alternative imaging selection strategies that should be widely deployed for patient benefit. These findings significantly advance stroke treatment, but at the expense of additional complexity that will likely require review of systems of care. Triage decisions are likely to be dictated by locally available human expertise, imaging, and interventional resources. Perfusion analysis equipment, software, and technicians are expensive resources that might not be immediately available in smaller hospitals. For institutions delivering intravenous thrombolysis for stroke, acquiring automated imaging capabilities will allow treatment of late time window patients, as well as rapid large vessel occlusion detection with bridging intravenous thrombolysis while in transit to thrombectomy-capable institutions. The trial findings should further stimulate policymakers to consider resource distribution across regional networks to ensure optimal delivery of stroke care. While these advances clearly expand the options for intravenous thrombolysis for late arrivals and for strokes of uncertain onset time, we must avoid any misperception that stroke is less of an emergency. Time is still brain, and the emphasis should remain on expediting treatment in the face of growing imaging complexities that inform critical triage and transfer decisions.

Disclosures

Dr Muir has served on advisory boards and received research support from Boehringer Ingelheim; advisory boards for Bayer and Daiichi-Sankyo; research support from Medtronic & Codman. The other author reports no conflicts.

References

1. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al; Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. *Lancet.* 2014;384:1929–1935. doi: 10.1016/S0140-6736(14)60584-5
2. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. *Neurology.* 2001;56:1015–1020. doi: 10.1212/wnl.56.8.1015
3. Wheeler HM, Mlynash M, Inoue M, Tipirnini A, Liggins J, Bammer R, et al; DEFUSE 2 Investigators. The growth rate of early DWI lesions is highly variable and associated with penumbral salvage and clinical outcomes following endovascular reperfusion. *Int J Stroke.* 2015;10:723–729. doi: 10.1111/ijs.12436

4. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, et al; DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. *Stroke.* 2005;36:66–73. doi: 10.1161/01.STR.0000149938.08731.2c
5. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, et al; DEDAS Investigators. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. *Stroke.* 2006;37:1227–1231. doi: 10.1161/01.STR.0000217403.66996.6d
6. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, et al; EPITHET Investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. *Lancet Neurol.* 2008;7:299–309. doi: 10.1016/S1474-4422(08)70044-9
7. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. *Lancet Neurol.* 2009;8:141–150. doi: 10.1016/S1474-4422(08)70267-9
8. Albers GW, von Kummer R, Truelsen T, Jensen JK, Ravn GM, Grønning BA, et al; DIAS-3 Investigators. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. *Lancet Neurol.* 2015;14:575–584. doi: 10.1016/S1474-4422(15)00047-2
9. von Kummer R, Mori E, Truelsen T, Jensen JS, Grønning BA, Fiebach JB, et al; DIAS-4 Investigators. Desmoteplase 3 to 9 Hours after major artery occlusion stroke: The DIAS-4 Trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke). *Stroke.* 2016;47:2880–2887. doi: 10.1161/STROKEAHA.116.013715
10. Ma H, Campbell BCV, Parsons MW, Churilov L, Levi CR, Hsu C, et al; EXTEND Investigators. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. *N Engl J Med.* 2019;380:1795–1803. doi: 10.1056/NEJMoa1813046
11. Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, et al; WAKE-UP Investigators. MRI-guided thrombolysis for stroke with unknown time of onset. *N Engl J Med.* 2018;379:611–622. doi: 10.1056/NEJMoa1804355
12. Ringleb P, Bendszus M, Bluhmki E, Donnan G, Eschenfelder C, Fatar M, et al. Extending the time window for intravenous thrombolysis in acute ischemic stroke using magnetic resonance imaging-based patient selection [published online April 4, 2019]. *Int J Stroke*. doi: 10.1177/1747493019840938
13. Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, et al; MR RESCUE Investigators. A trial of imaging selection and endovascular treatment for ischemic stroke. *N Engl J Med.* 2013;368:914–923. doi: 10.1056/NEJMoa1212793
14. Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al; DAWN Trial Investigators. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. *N Engl J Med.* 2018;378:11–21. doi: 10.1056/NEJMoa1706442
15. Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al; DEFUSE 3 Investigators. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. *N Engl J Med.* 2018;378:708–718. doi: 10.1056/NEJMoa1713973
16. Dani KA, Thomas RG, Chappell FM, Shuler K, Muir KW, Wardlaw JM. Systematic review of perfusion imaging with computed tomography and magnetic resonance in acute ischemic stroke: heterogeneity of acquisition and postprocessing parameters: a translational medicine research collaboration multicentre acute stroke imaging study. *Stroke.* 2012;43:563–566. doi: 10.1161/STROKEAHA.111.629923
17. Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. *N Engl J Med.* 2012;366:1099–1107. doi: 10.1056/NEJMoa1109842
18. Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al; EXTEND-IA TNK Investigators. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. *N Engl J Med.* 2018;378:1573–1582. doi: 10.1056/NEJMoa1716405
19. Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med.* 2015;372:1009–1018. doi: 10.1056/NEJMoa1414792
20. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al; SWIFT PRIME Investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. *N Engl J Med.* 2015;372:2285–2295. doi: 10.1056/NEJMoa1415061
21. Campbell BCV, Ma H, Ringleb PA, Parsons MW, Churilov L, Bendszus M, et al. Extending thrombolysis to 4.5–9 h and wake-up stroke using perfusion imaging: A systematic review and meta-analysis of individual patient data. *Lancet*. 2019;394:139–147.

KEY WORDS: clinical trial ■ collateral circulation ■ computed tomography magnetic resonance imaging ■ perfusion imaging ■ thrombectomy